CerSci Therapeutics cersci.com

CerSci Therapeutics is poised to deliver a new generation of non-opioid medicines to treat acute postoperative and chronic neuropathic pain (painful diabetic neuropathy). CT-044, CerSci's lead molecular asset, has demonstrated efficacy across a battery of incisional, inflammatory, and neuropathic pain models with a clean animal safety package. CT-044 has completed IND-enablement and has commenced Phase I clinical trial to investigate safety and tolerability in healthy normal volunteers.

CerSci Therapeutics is poised to deliver a new generation of non-opioid medicines to treat acute postoperative and chronic neuropathic pain (painful diabetic neuropathy). CT-044, CerSci's lead molecular asset, has demonstrated efficacy across a batte...Show all

Company (Alive / Active)

All investors data 4 Investors

• JDH Investment Management
• National Institute of Neurological Disorders and Stroke
• National Institute on Drug Abuse
• National Institutes of Health

There is no Investors data available for this company. Please select another tab.

There is no Board of Directors data available for this company. Please select another tab.

Board Members

There is no Competitors data available for this company. Please select another tab.

Competitors

See all 0 competitors

Patents